Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Low-Dose Nab-Paclitaxel/Carboplatin in Advanced Squamous NSCLC
NCT07647094Phase 2Recruiting
- Sponsor
- Quzhou People's Hospital
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, paclitaxel, carboplatin in non-small cell lung cancer (NSCLC), sponsored by Quzhou People's Hospital. Started Nov 2025; status: recruiting.
02
Drugs
serplulimabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07647094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647094.